SGLT2 versus DPP4 inhibitors for type 2 diabetes

被引：15
|
作者：
Scheen, Andre J. [1 ,2 ]
机构：
[1] CHU Sart Tilman, Dept Med, Div Diabet Nutr & Metab Disorders, B-4000 Liege, Belgium
[2] CHU Sart Tilman, Dept Med, Clin Pharmacol Unit, B-4000 Liege, Belgium
来源：
LANCET DIABETES & ENDOCRINOLOGY | 2013年 / 1卷 / 03期
关键词：
CANAGLIFLOZIN;
D O I：
10.1016/S2213-8587(13)70095-0
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：168 / 170
页数：4
相关论文
共 50 条
  • [1] Type 2 Diabetes: SGLT2 Inhibitors and DPP4 Inhibitors in Comparison
    Simon, Annika
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2023, 148 (16) : 1002 - 1002
  • [2] Type 2 Diabetes: SGLT2 Inhibitors and DPP4 Inhibitors in Comparison Comment
    Menzen, Markus
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2023, 148 (16) : 1003 - 1003
  • [3] Clinical Outcomes in Patients with Type 2 Diabetes Newly Initiating SGLT2 or DPP4 Inhibitors
    Adimadhyam, Sruthi
    Isaman, Danielle
    Weckstein, Andrew
    Payne, Emma
    Yu, Edward
    Louder, Anthony
    Reynolds, Shannon L.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 36 - 37
  • [4] Association Between SGLT2 Inhibitors vs DPP4 Inhibitors and Renal Outcomes Among Patients With Type 2 Diabetes
    Au, Philip C. M.
    Tan, Kathryn C. B.
    Cheung, Bernard M. Y.
    Wong, Ian C. K.
    Li, Hang-Long
    Cheung, Ching-Lung
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (07): : E2962 - E2970
  • [5] Risk of Nephrolithiasis Associated With SGLT2 Inhibitors Versus DPP4 Inhibitors Among Patients With Type 2 Diabetes: A Target Trial Emulation Study
    Shin, Anna
    Shin, Ju-Young
    Kang, Eun Ha
    DIABETES CARE, 2025, 48 (02)
  • [6] Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes
    Zhou, Jiandong
    Liu, Xuejin
    Chou, Oscar Hou-In
    Li, Lifang
    Lee, Sharen
    Wong, Wing Tak
    Zhang, Qingpeng
    Chang, Carlin
    Liu, Tong
    Tse, Gary
    Jing, Fengshi
    Cheung, Bernard Man Yung
    RHEUMATOLOGY, 2023, 62 (04) : 1501 - 1510
  • [7] Lower Risks of New-Onset Hepatocellular Carcinoma in Patients With Type 2 Diabetes Mellitus Treated With SGLT2 Inhibitors Versus DPP4 Inhibitors
    Chou, Oscar Hou In
    Ning, Jing
    Chan, Raymond Ngai Chiu
    Chung, Cheuk To
    Huang, Helen
    Ng, Kenrick
    Dee, Edward Christopher
    Lee, Sharen
    Kaewdech, Apichat
    Chow, Ariel K. Man
    Man, Nancy Kwan
    Liu, Tong
    Jing, Fengshi
    Cheung, Bernard Man Yung
    Tse, Gary
    Zhou, Jiandong
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2024, 22 (2D):
  • [8] Efficacy/safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes
    Scheen, Andre J.
    DIABETES & METABOLISM, 2021, 47 (06)
  • [9] Risk of hyperkalaemia in patients with type 2 diabetes mellitus prescribed with SGLT2 versus DPP-4 inhibitors
    Wu, Mei-zhen
    Teng, Tiew-Hwa Katherine
    Tsang, Christopher Tze-Wei
    Chan, Yap-Hang
    Lee, Chi-Ho
    Ren, Qing-wen
    Huang, Jia-Yi
    Cheang, Iok-fai
    Tse, Yi-Kei
    Li, Xin-li
    Xu, Xin
    Tse, Hung-Fat
    Lam, Carolyn S. P.
    Yiu, Kai-Hang
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2024, 10 (01) : 45 - 52
  • [10] Kidney outcomes with SGLT2 inhibitor versus DPP4 inhibitor use in older adults with diabetes
    Suzuki, Yuta
    Kaneko, Hidehiro
    Okada, Akira
    Komuro, Jin
    Ko, Toshiyuki
    Fujiu, Katsuhito
    Takeda, Norifumi
    Morita, Hiroyuki
    Nishiyama, Akira
    Ieda, Masaki
    Node, Koichi
    Yasunaga, Hideo
    Nangaku, Masaomi
    Komuro, Issei
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024,
12345